$SUPN buyung $SAGE for $8.50 upfront plus a CVR that can be worth up to $3.50. globenewswire.com/news-rele... CVR pas out if these milestones are met: 1) $1.00 per share if in any calendar year between closing and end of 2027, annual net sales of ZURZUVAE allocable to Supernus reach $250 million or more in the US 2) $1.00 per share if in any calendar year between closing and end of 2028, annual net sales of ZURZUVAE allocable to Supernus reach $300 million or more in the US 3) $1.00 per share if in any calendar year between closing and end of 2030, annual net sales of ZURZUVAE allocable to Supernus reach $375 million or more in the US 4) $0.50 per share at first commercial sale in Japan to a third-party customer after regulatory approval for ZURZUVAE for the treatment of major depressive disorder (MDD) in Japan by June 30, 2026.